Background: Mucoepidermoid carcinoma (MEC), which is primarily found in the salivary glands, is rarely seen in the breast. These tumors usually develop from squamous and mucus-secreting cells. Histological grading is an important prognostic factor. Case Report: We present herein a case of a 69-year-old female patient with a painful mass in the left breast. Of importance is that, in addition to MEC, the patient had a wide area of scar tissue secondary to a burn that completely occupied the left bottom quadrant of the abdomen and retracted the left nipple up to the left upper quadrant. Fine needle aspiration biopsy was negative, and a lumpectomy was performed. Because the pathology results were consistent with MEC, modified radical mastectomy with subsequent adjuvant chemotherapy and radiotherapy was performed. The patient remained disease-free for 12 months after the treatment. In addition to a discussion of this case, we performed a review of the clinicopathological characteristics of 30 cases with breast MEC reported in the English language literature between 1979 and 2010. Conclusions: MEC of the breast is a rarely seen tumor, and this is the first report of MEC in a breast affected by burn scars.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.